|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
PDGM is another biotech in lock-up expiration hell. Shares unlocked in January '01, and the 144s have been pouring out. It seems to be mostly VC at this point.
This link should work indefinitely for keeping track of the insider transactions:
From their website:
>>Paradigm Genetics is industrializing the process of gene function determination for four major sectors of the global economy: human health, nutrition, crop production, and industrial products.<<
It is my understanding that charecterization of gene function is a major bottleneck in drug discovery. Their Gene Function Factory technology is manifest in workstations, so PDGM could arguably be a tool company.
|© 2022 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|